Published in Muscle Nerve on May 01, 2006
Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs. Elife (2015) 1.10
Cation dyshomeostasis and cardiomyocyte necrosis: the Fleckenstein hypothesis revisited. Eur Heart J (2011) 0.96
Beta2 adrenergic agonist, clenbuterol, enhances working memory performance in aging animals. Neurobiol Aging (2007) 0.93
Muscle plasticity and β₂-adrenergic receptors: adaptive responses of β₂-adrenergic receptor expression to muscle hypertrophy and atrophy. J Biomed Biotechnol (2011) 0.86
Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle. Muscle Nerve (2007) 0.83
Relative myotoxic and haemodynamic effects of the beta-agonists fenoterol and clenbuterol measured in conscious unrestrained rats. Exp Physiol (2006) 0.77
Randomized, double-blind, and placebo-controlled trial of clenbuterol in denervated muscle atrophy. ISRN Pharm (2011) 0.77
Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from Gastrocnemius Muscle. PLoS One (2015) 0.75
Effects of clenbuterol, a β₂-adrenergic agonist, on sizes of masseter, temporalis, digastric, and tongue muscles. Open Dent J (2009) 0.75
SIRIUS RED F3BA AS A STAIN FOR CONNECTIVE TISSUE. Arch Pathol (1964) 2.78
Beta-agonist-induced alterations in organ weights and protein content: comparison of racemic clenbuterol and its enantiomers. Chirality (2000) 1.43
Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res (1989) 1.38
Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J (1989) 1.30
Chronic effects of beta 2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Rep (1984) 1.26
Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. J Physiol (2003) 1.25
Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist. Am J Physiol (1988) 1.21
Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve (2002) 1.20
Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: the same or separate death pathways? Exp Physiol (2004) 1.20
Network integration of the adrenergic system in cardiac hypertrophy. Cardiovasc Res (2004) 1.16
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res (2004) 1.15
Effects of clenbuterol and propranolol on muscle mass. Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy. Biochem J (1989) 1.07
Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation. Am J Physiol (1992) 1.06
beta2-Adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle. J Appl Physiol (1985) (2004) 0.98
A physiological level of clenbuterol does not prevent atrophy or loss of force in skeletal muscle of old rats. J Appl Physiol (1985) (2000) 0.96
Catecholamines inhibit Ca(2+)-dependent proteolysis in rat skeletal muscle through beta(2)-adrenoceptors and cAMP. Am J Physiol Endocrinol Metab (2001) 0.95
Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J Appl Physiol (1985) (2002) 0.95
The action of the beta-agonist clenbuterol on protein metabolism in innervated and denervated phasic muscles. Biochem J (1989) 0.93
Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway. J Appl Physiol (1985) (2005) 0.92
Effects of beta 2-agonist administration and exercise on contractile activation of skeletal muscle fibers. J Appl Physiol (1985) (1996) 0.91
Interaction between clenbuterol and run training: effects on exercise performance and MLC isoform content. J Appl Physiol (1985) (1996) 0.91
Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin Sci (Lond) (2000) 0.91
Effect of clenbuterol on sarcoplasmic reticulum function in single skinned mammalian skeletal muscle fibers. Am J Physiol (1998) 0.90
Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am J Physiol Regul Integr Comp Physiol (2000) 0.89
Clenbuterol reduces soleus muscle fatigue during disuse in aged rats. Muscle Nerve (2001) 0.88
Effects of clenbuterol on contractile and biochemical properties of skeletal muscle. Med Sci Sports Exerc (1996) 0.87
Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. Circulation (1995) 0.86
Effect of a selective beta 2-adrenergic agonist (clenbuterol) on energy balance and body composition in normal and protein deficient rats. Biosci Rep (1987) 0.85
Chronic beta-agonist administration affects cardiac function of adult but not old rats, independent of beta-adrenoceptor density. Am J Physiol Heart Circ Physiol (2005) 0.84
Characterisation of isoprenaline myotoxicity on slow-twitch skeletal versus cardiac muscle. Int J Cardiol (2002) 0.84
Dose-dependent apoptotic and necrotic myocyte death induced by the beta2-adrenergic receptor agonist, clenbuterol. Muscle Nerve (2005) 0.84
Stimulation of actin and myosin synthesis in rat gastrocnemius muscle by clenbuterol; evidence for translational control. Comp Biochem Physiol C (1992) 0.83
Chronic clenbuterol administration negatively alters cardiac function. Med Sci Sports Exerc (2002) 0.83
Clenbuterol-induced fiber type transition in the soleus of adult rats. Eur J Appl Physiol Occup Physiol (1996) 0.83
Characterization of adrenoceptor involvement in skeletal and cardiac myotoxicity Induced by sympathomimetic agents: toward a new bioassay for beta-blockers. J Cardiovasc Pharmacol (2003) 0.82
Effect of sympathetic denervation on the rate of protein synthesis in rat skeletal muscle. Am J Physiol Endocrinol Metab (2004) 0.81
Different beta-adrenergic receptor density in different rat skeletal muscle fibre types. Pharmacol Toxicol (1995) 0.81
Clenbuterol diminishes aerobic performance in horses. Med Sci Sports Exerc (2002) 0.81
Denervation increases clenbuterol sensitivity in muscle from young rats. Muscle Nerve (1992) 0.80
Tissue distribution of clenbuterol in the horse. J Vet Pharmacol Ther (2004) 0.79
Tissue specific and variable collagen proliferation in Swiss albino mice treated with clenbuterol. Physiol Res (2005) 0.77
Management of acute osteoporotic vertebral fractures: a nonrandomized trial comparing percutaneous vertebroplasty with conservative therapy. Am J Med (2003) 2.66
Clinical outcomes after acute osteoporotic vertebral fractures: a 2-year non-randomised trial comparing percutaneous vertebroplasty with conservative therapy. Med J Aust (2006) 2.40
SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J (2003) 2.16
Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. J Mol Cell Cardiol (2005) 1.67
Maximizing patient benefit from cardiac resynchronization therapy with the addition of structured exercise training: a randomized controlled study. J Am Coll Cardiol (2009) 1.57
Discrepancy between cardiac and physical functional reserves in stroke. Stroke (2012) 1.47
Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells. J Biol Chem (2007) 1.36
Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: the same or separate death pathways? Exp Physiol (2004) 1.20
Proteomic investigation of changes in human vastus lateralis muscle in response to interval-exercise training. Proteomics (2009) 1.11
Have recent vertebroplasty trials changed the indications for vertebroplasty? Cardiovasc Intervent Radiol (2010) 1.09
Histomorphometric analysis of fracture healing cascade in acute osteoporotic vertebral body fractures. Bone (2006) 1.06
Cardiomyocyte death and the ageing and failing heart. Exp Physiol (2003) 1.06
A prospective longitudinal evaluation of the benefits of epicardial lead placement for cardiac resynchronization therapy. Europace (2009) 1.02
beta2-Adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle. J Appl Physiol (1985) (2004) 0.98
Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J Appl Physiol (1985) (2002) 0.95
How do different indicators of cardiac pump function impact upon the long-term prognosis of patients with chronic heart failure? Am Heart J (2005) 0.87
Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat. Exp Physiol (2005) 0.86
Characterisation of isoprenaline myotoxicity on slow-twitch skeletal versus cardiac muscle. Int J Cardiol (2002) 0.84
Exercise duration and peak systolic blood pressure are predictive of mortality in ambulatory patients with mild-moderate chronic heart failure. Cardiology (2005) 0.84
Dose-dependent apoptotic and necrotic myocyte death induced by the beta2-adrenergic receptor agonist, clenbuterol. Muscle Nerve (2005) 0.84
Cardiac stem cell-based myocardial regeneration: towards a translational approach. Cardiovasc Hematol Agents Med Chem (2008) 0.84
Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle. Muscle Nerve (2007) 0.83
The effect of 48 weeks of aerobic exercise training on cutaneous vasodilator function in post-menopausal females. Eur J Appl Physiol (2009) 0.83
Characterization of adrenoceptor involvement in skeletal and cardiac myotoxicity Induced by sympathomimetic agents: toward a new bioassay for beta-blockers. J Cardiovasc Pharmacol (2003) 0.82
Influence of age, sex, and aerobic capacity on forearm and skin blood flow and vascular conductance. Eur J Appl Physiol (2010) 0.82
Relative toxicity of cardiotonic agents: some induce more cardiac and skeletal myocyte apoptosis and necrosis in vivo than others. Cardiovasc Toxicol (2005) 0.82
Comparison and relation of indirect and direct dynamic indexes of cardiac pumping capacity in chronic heart failure. Am J Cardiol (2005) 0.81
Microbial cellulose wound dressing in the treatment of nonhealing lower extremity ulcers. Wounds (2009) 0.78
A study of presbycardia, with gender differences favoring ageing women. Int J Cardiol (2008) 0.78
Correcting data for body size may confound results. Chest (2006) 0.78
Comparison of plasma N-brain natriuretic peptide, peak oxygen consumption, and left ventricular ejection fraction for severity of chronic heart failure. Am J Cardiol (2004) 0.77
Relative myotoxic and haemodynamic effects of the beta-agonists fenoterol and clenbuterol measured in conscious unrestrained rats. Exp Physiol (2006) 0.77
Is plasma N-BNP a good indicator of the functional reserve of failing hearts? The FRESH-BNP study. Eur J Heart Fail (2004) 0.77
Is uremic cardiomyopathy a direct consequence of chronic kidney disease? Expert Rev Cardiovasc Ther (2014) 0.76
Vertebroplasty for acute osteoporotic fractures - position statement from the Interventional Radiology Society of Australasia. J Med Imaging Radiat Oncol (2011) 0.76
200+ years of a misunderstood drug for treating chronic heart failure: digoxin, why and how should we continue using it? Int J Cardiol (2012) 0.76
Assessing the effect of ACE inhibitors on exercise tolerance: a question of study design. Eur Heart J (2004) 0.75
Impaired left ventricular function in obesity? Eur Heart J (2005) 0.75
VALUE: analysis of results. Lancet (2004) 0.75
Peak exercise responses in heart failure: back to basics. Eur Heart J (2009) 0.75
Relationship of serum cardiac markers following successful percutaneous coronary intervention and subsequent exercise capacity in patients with chronic stable angina: a pilot study. Cardiology (2004) 0.75
Reduced cardiac functional reserve and quality of life in adults with GH deficiency. Clin Endocrinol (Oxf) (2009) 0.75
Troponin leak in heart failure: moving forward to arrest cardiomyocyte attrition and promote myocardial regeneration. Int J Cardiol (2012) 0.75
New evidence of cardiac dysfunction associated with renal impairment. Int J Cardiol (2011) 0.75
Short-axis 2D strain from speckle tracking predicts echocardiographic response to cardiac resynchronization therapy. Echocardiography (2010) 0.75
Atrial Fibrillation reduces the Functional REServe of the Heart by a fifth: a pilot FRESH-AF study. Int J Cardiol (2013) 0.75
Cardiac functional reserve is diminished in growth hormone-deficient adults. Cardiovasc Ther (2009) 0.75
A parallel open-label trial to evaluate microbial cellulose wound dressing in the treatment of diabetic foot ulcers. Int Wound J (2010) 0.75
Mechanical properties of the latissimus dorsi muscle after cyclic training. J Appl Physiol (1985) (2002) 0.75
Cardiac functional benefits of ivabradine therapy in patients with severe heart failure. Int J Cardiol (2012) 0.75
English translation of abstracts of original articles published in German 50 years ago on the discovery of aldosterone. Int J Cardiol (2004) 0.75
A mechanistic investigation into how long-term resynchronization therapy confers ongoing cardiac functional benefits and improved exercise capacity. Am J Cardiol (2009) 0.75
Efficacy of lifestyle intervention on peak exercise cardiac power output and reserve in premenopausal obese females: a randomised pilot study. Int J Cardiol (2007) 0.75